Balazs Halmos, MD

Articles

Dr. Halmos on the Efficacy of COVID-19 Vaccines in Patients With Cancer

June 25th 2021

Balazs Halmos, MD, discusses the efficacy of the COVID-19 vaccines in patients with cancer.

Dr. Halmos on the Emergence of KRAS-Targeted Therapies in Lung Cancer

January 21st 2021

Balazs Halmos, MD, MS, discusses the emergence of KRAS-targeted therapies in lung cancer.

Early-Stage NSCLC Is Ripe for Change

February 13th 2019

Following a 2-decade lull in early-stage lung cancer, we are now seeing much better-designed neoadjuvant and adjuvant studies based on proper biomarker selection, as well as optimized treatment choices founded upon recent advances in the metastatic setting.

Dr. Halmos on MET Mutations in Patients With NSCLC

November 15th 2016

Balazs Halmos, MD, director, Thoracic Oncology, director, Clinical Cancer Genomics, Montefiore Medical Center, discusses the prevalence of MET mutations in patients with non–small cell lung cancer (NSCLC).

Dr. Halmos on Detecting Actionable Mutations in Patients With Lung Cancer

October 7th 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, comments on the detection of actionable mutations in patients with lung cancer.

Dr. Halmos on the Impact of EGFR Inhibitors on the Treatment of Lung Cancer

April 28th 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the impact of EGFR inhibitors on the treatment of lung cancer.

Dr. Halmos on Checkpoint Inhibitors in Lung Cancer

April 2nd 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the anti-PD-L1 antibody MK-3475 and the challenge of integrating immunotherapies into the field of lung cancer.

Dr. Halmos on the Implications of the IPASS Study

March 26th 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the implication of the IPASS study.